Biophytis and AskHelpU Form Co-Development Partnership in China

Biophytis, a biotechnology company specializing in treatments for age-related diseases, has entered a co-development agreement with AskHelpU, China’s largest patient association for amyotrophic lateral sclerosis (ALS). This collaboration will focus on evaluating the efficacy of BIO101, Biophytis' leading drug candidate, in treating ALS. If initial results are promising, the partnership plans to proceed to larger-scale clinical trials. The agreement combines Biophytis’ drug development expertise with AskHelpU’s insights into ALS, potentially expanding BIO101’s therapeutic applications.

AskHelpU will engage top Chinese universities and research labs for this project. ALS is a progressively debilitating disease with no cure, affecting approximately 200,000 individuals in China alone. This collaboration represents a significant opportunity for Biophytis and showcases BIO101’s potential in addressing rare neuromuscular diseases.